Print page


Date of issue: December 2022
Version: 3

This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a pregnancy reporting form. Please encourage all women to complete an online reporting form.

A corresponding patient information leaflet on Use of agomelatine in pregnancy is available at


Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist used in the treatment of major depressive disorder. It also induces a phase advance of sleep, body temperature decline, and the onset of melatonin release.

The available evidence relating to the safety of agomelatine use in pregnancy is highly limited. Animal studies performed by the manufacturer have not identified adverse effects on embryo/fetal, pre- or postnatal development. There are no published cases of agomelatine use in human pregnancy.

Where agomelatine is being used in the treatment of psychiatric conditions, the risk to both woman and fetus from relapse of the maternal condition as a consequence of discontinuing the drug or reducing the dose during pregnancy should be carefully considered.

Due to the lack of safety data, additional fetal monitoring may be considered appropriate in cases where agomelatine exposure has occurred during pregnancy. Although there are no data specific to agomelatine, as with any centrally acting drug, neonatal withdrawal may be expected following chronic use or use near term. It may therefore be advisable to monitor infants for signs of withdrawal after delivery.

Exposure to agomelatine at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy. However, other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.


This document is regularly reviewed and updated. Only use full UKTIS monographs downloaded directly from to be sure you are using the most up-to-date version. The summaries of these monographs are openly available on

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to health care professionals at

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from or to ensure you are using the most up-to-date version.